Diabetes Research Centers (P30 Clinical Trial Optional)

About this funding opportunity

This Notice of Funding Opportunity (NOFO) invites applications for Diabetes Research Centers (DRCs) that are designed to support and enhance the national research effort in diabetes, its complications, and related endocrine and metabolic diseases. The purpose of this Centers program is to bring together basic and clinical investigators to enhance communication, multidisciplinary collaboration, and effectiveness of ongoing research in Diabetes Research Center topic areas. By providing shared access to specialized technical resources (research cores) and supporting a Pilot and Feasibility Program (P&F), DRCs are intended to create an environment that provides the capability for accomplishments greater than those that would be possible by individual research project grant support alone. New Center programs that bring in diverse perspectives, propose unique scientific themes, or provide innovative resources are encouraged. Emphasis will be placed on Center programs that propose enhanced synergies with other NIDDK-funded programs as well as providing a rich mentoring environment for future diabetes researchers.

Topic areas: Life Sciences and Health, Education and Training.

Funding amount

This grant provides Up to $1M in funding, up to $1M per award.

Deadline

Applications are due Jan 27, 2027. Confirm the exact closing time on the official program page before applying.

Who can apply

This opportunity is open to the following applicant types:

• Public Authorities
• NGOs
• Large Company
• SME
• University
• Other

Eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility. Special Instructions for this NOFO: Only one application is allowed per institution. Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Agency

Diabetes Research Centers (P30 Clinical Trial Optional) is administered by National Institutes of Health (NIH), listed via Grants.gov.